share_log

Clearmind Medicine | CORRESP: CORRESP

SEC announcement ·  Feb 14 22:21
Summary by Moomoo AI
Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more